Publications

Publications, Books, Book Chapters and Reviews by Prof. Marcus Maurer, MD

Use: Start with an overview of all publications. Use tag links to list selected documents or to list an entire category, e.g. Original Work, Books, Book Chapters, Reviews. If you know what you are looking for, enter this term in the search field.

Repeat treatment with icatibant for multiple hereditary angioedema attacks: FAST-2 open-label study

Filename 173. Bas et al.,Repeat treatm. icatibant HAE ALLERGY 2013.pdf
Filesize 304.85 KB
Version o.173
Date added June 6, 2020
Downloaded 0 times
Category Original Work
Tags bradykinin B2 receptor antagonist, For Angioedema Subcutaneous Treatment-2 (FAST-2), Hereditary Angioedema, Icatibant, open-label extension phase
Authors Bas, M., Greve, J., Hoffmann, T., Reshef, A., Aberer, W., Maurer, M. Kivity, S., Farkas, H., Floccard, B., Arcoleo, F., Martin, L., Sitkauskiene, B., Bouillet, L., Schmid-Grendelmeier, P., Li, H., and Zanichelli, A.
Citation Bas, M., Greve, J., Hoffmann, T., Reshef, A., Aberer, W., Maurer, M. Kivity, S., Farkas, H., Floccard, B., Arcoleo, F., Martin, L., Sitkauskiene, B., Bouillet, L., Schmid-Grendelmeier, P., Li, H., and Zanichelli, A.: Repeat treatment with icatibant for multiple hereditary angioedema attacks: FAST-2 open-label study. Allergy 2013: 68; 1452-1459.
Corresponding authors Bas, M.
DocNum O.173
DocType PDF
Edition; Page 68; 1452-1459
IF 5.99
Publisher Allergy
ReleaseDate 2013

Background: The For Angioedema Subcutaneous Treatment (FAST)-2, a phase III, double-blind, randomized, multicenter, placebo-controlled study (ClinicalTri als.gov identifier: NCT00500656), established the efficacy and safety of single injections of icatibant, a bradykinin B2 receptor antagonist, in the treatment of hereditary angioedema (HAE) attacks. Here, we evaluate the efficacy and safety of repeated treatment with icatibant in adult patients experiencing HAE attacks during the FAST-2 open-label extension (OLE) phase.

Methods: Patients completing the controlled phase were eligible to participate in the OLE phase and receive open-label icatibant (30 mg subcutaneously) for the treatment of cutaneous, abdominal, and/or laryngeal HAE attack(s) severe enough to warrant treatment. Time to onset of symptom relief was calculated for each attack. Descriptive analyses (median, 95% CIs) were performed for all attacks; post hoc analyses were conducted in patients with at least five icatibant- treated attacks throughout the FAST-2 OLE phase. Safety was also monitored.

Results: Fifty-four patients received icatibant for 374 attacks (176 cutaneous, 168 abdominal, and 30 laryngeal). For cutaneous and/or abdominal attacks (attacks 2–5), the median times to onset of symptom relief ranged between 2.0 and 2.5 h. For all laryngeal attacks, the median times to regression (start of improvement) of symptoms ranged between 0.3 and 4.0 h. Post hoc analyses showed that the overall median time to onset of symptom relief was 2.0 h. Overall, 89.8% of attacks resolved with a single icatibant injection. No drug-related serious adverse events were reported.

Conclusions: These findings have demonstrated the efficacy and safety of repeated icatibant treatment for HAE attacks.

 

(Last update: 12.2023)

Number of original publications in peer-reviewed journals:580
Number of reviews in peer-reviewed journals:210
Number of publications (original work and reviews) in peer-reviewed journals:790
Cumulative IF for original publications in peer-reviewed journals:4196.39
Cumulative IF for reviews in peer-reviewed journals:1409.32
Cumulative IF of publications (original work & reviews) in peer-reviewed journals:5605.71
Total number of citations: 36,836, h-index: 99 (Web of Science December 2023)36836

Download-Information

To be able to download the offered contents, you have to login. If you do not know the login, please write me your request.